CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Light Adjustable lens (LAL) and Light Delivery Device (LDD) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05202808
NCT05202808N/ACompleted
CompareCT.gov

RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

RxSight, Inc.·interventional·Posted Jan 24, 2022·Updated Apr 20, 2025

In Brief

A clinical study evaluating Light Adjustable lens (LAL) and Light Delivery Device (LDD) and Control IOL for Aphakia and Cataract. Completed, enrolled 500 participants across 14 sites.

Detailed Summary

The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Cataract
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJan 24, 2022
Enrollment StartDec 3, 2021
Primary CompletionSep 11, 2024
Study CompletionDec 16, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.4 years ago

Interventions

Light Adjustable lens (LAL) and Light Delivery Device (LDD)device

Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments

Control IOLdevice

Control treatment group will receive a Control IOL